Posted: MedImmune Inc. v. Genentech Inc. Supreme Court Oral Argument

Today, the Supreme court heard oral arguments on MedImmune Inc. v. Genentech Inc. At issue in the case is whether a company must stop paying royalties on a patent license in order to challenge the validity of the patent. MedImmune is paying licensing fees to Genentech on antibody technology used in MedImmune's childhood respiratory drug, Synagis. At the same time, Medimmune wants to challenge Genentech's patent in court.

The transcript for the oral arguments have been posted by the Supreme Court, and can be downloaded here.